MORE VIDEOS
Explore more

Lymphoma - Hodgkin - Childhood

Hodgkin's lymphoma (Hodgkin's disease) - Symptoms and treatment. How to detect lymphoma?
Hodgkin's lymphoma (Hodgkin's disease) - Symptoms and treatment. How to detect lymphoma? administrator 0 Views • 2 years ago

Hodgkin lymphoma is one of the most frequent lymphomas in the world. Even it is frequent lymphoma, generally this malignancy still rare. It affects 2-3 person per 100 thousand.
About 40 % of this malignancy is associated with Epstein-Barr Virus (EBV) infection commonly in teenage.
Hodgkin Lymphoma is classified two important categories. First is classical Hodgkin lymphoma, and nodular lymphocyte-predominant Hodgkin lymphoma. 95 % of cases are classical form.
Most common sign of Hodgkin lymphoma is enlarged lymph nodes around neck. Or axillary region.
60-70 % of cases enlarged lymph nodes are noted around cervical area. This lymph nodes aren’t painful.
30% of cases are axillary lymph nodes. And around 50 % of cases mediastinal lymph nodes also involved.
Only 10-15 % of patients with Hodgkin Lymphoma have extranodal disease, and the commonly affected organs are bone, bone marrow, lung, and liver.
Other symptoms include:
Fevers, drenching night sweats and unintentional weight loss.
These symptoms aren’t specific for Hodgkin lymphoma and presence this symptoms doesn’t mean Hodgkin lymphoma itself.
This 3 symptoms collectively is called B symptoms.
Fever is considered temperature more than 38 c degree.
Weight loss of 10% or more of baseline weight in the previous 6 months.
Weight loss and fever are more important symptoms then night sweats isolated.
So, Night sweats alone do not confer an adverse prognosis.
Other symptoms include:
Pruritus, especially after bathing or after ingesting alcohol.
Fatigue.
Risk Factors for Hodgkin lymphoma include:
Being in early adulthood (aged 20–39 years) (most often) or late adulthood (aged 65 years and older) (less often).
Being male.
Having a previous infection with the Epstein-Barr virus in the teenage years or early childhood.
Having a first-degree relative with Hodgkin Lymphoma.
Diagnosis:
Hodgkin lymphoma cannot be diagnosed with a blood test.
Although the complete blood test count can have some role, the measures the levels of different cells in the blood.
For example, if the lymphoma invades the bone marrow (where new blood cells are made) a person might have anemia (not enough red blood cells). A high white blood cell count is another possible sign of Hodgkin Lymphoma, although it can also be caused by infection.
A Hodgkin lymphoma is marked by the presence of a type of cell called the Reed–Sternberg cell
The diagnosis of HL involves a multistage process. The removal and histopathological analysis of a lymph node or punch biopsy of another affected organ is the method of choice for diagnosis. Thus, pathological expert review is recommended. A fine needle biopsy alone is only sufficient if sufficient material for histopathological diagnosis can be obtained.
Other risk factors are genetic predisposition (high incidence among patient's relatives), immunodeficiency states, and environmental factors (high incidence in farmers, woodworkers, and meat processors).

Hodgkin lymphoma has an excellent overall prognosis with approximately an 80% cure rate.
The history of HL treatment represents a remarkable success story in which HL has turned from an incurable disease to a neoplasm with an excellent prognosis. First-line treatment with stage-adapted treatment consisting of chemotherapy and/or radiotherapy results in cure rates of approximately 80%. Second-line treatment mostly consists of intensive salvage chemotherapy followed by high-dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT).

Standard treatment in the United States (US) consists of ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine). In Germany, the BEACOPP regimen (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) is more popular. A third regimen that is used is Stanford V (doxorubicin, vinblastine, mechlorethamine, vincristine, bleomycin, etoposide, and prednisone).

By Blausen Medical Communications, Inc. - see ticket for details, CC BY 3.0, https://commons.wikimedia.org/....w/index.php?curid=27
By Cancer Research UK - Original email from CRUK, CC BY-SA 4.0, https://commons.wikimedia.org/....w/index.php?curid=34
By Emmanuelm - Own work, CC BY 3.0, https://commons.wikimedia.org/....w/index.php?curid=10
By JHeuser - JHeuser, CC BY-SA 3.0, https://commons.wikimedia.org/....w/index.php?curid=78

Pronounce Medical Words ― Stage III Childhood Hodgkin Lymphoma
Pronounce Medical Words ― Stage III Childhood Hodgkin Lymphoma administrator 2 Views • 2 years ago

This video shows you how to say Stage III Childhood Hodgkin Lymphoma.

How would you pronounce Stage III Childhood Hodgkin Lymphoma?
Conversations With History: The Story of Hodgkin's Disease
Conversations With History: The Story of Hodgkin's Disease administrator 2 Views • 2 years ago

Harry Kreisler welcomes Charlotte DeCroes Jacobs, M.D., to discuss the development of a cure for Hodgkin's lymphatic cancer. Dr. Jacobs characterizes the challenges of being both an oncologist and biographer. She traces the history of Hodgkin's disease including the contributions of scientists who identified the cancer, its distinctive pattern of moving through the lymph system, and other clues that led to a cure. Focusing on the career of Stanford's Dr. Henry Kaplan, she describes his qualities as a scientist and clinician, and the work of Dr.Vincent DeVita in developing the drug used in the treatment of Hodgkins Disease. Series: Conversations with History [10/2010] [Health and Medicine] [Show ID: 19846]
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma
Less aggressive approaches in relapsed/refractory Hodgkin lymphoma administrator 3 Views • 2 years ago

Alison Moskowitz, MD, Memorial Sloan Kettering Cancer Center, New York City, NY, highlights areas of unmet need for patients with relapsed/refractory Hodgkin lymphoma (HL), including personalized, less aggressive approaches in the second-line setting, and potentially removing transplantation from the treatment approach for favorable patients with Hodgkin lymphoma. This interview took place at the Update on Hodgkin Lymphoma 2021, a Virtual ISHL event.
Current treatment strategies for newly diagnosed Hodgkin lymphoma
Current treatment strategies for newly diagnosed Hodgkin lymphoma administrator 2 Views • 2 years ago

David J. Straus, MD, Memorial Sloan-Kettering Cancer Center, New York, NY, outlines the current treatment strategies in newly diagnosed Hodgkin lymphoma, and explores the use of radiotherapy in some patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
How should we approach the adolescent/young adult Hodgkin lymphoma patient?
How should we approach the adolescent/young adult Hodgkin lymphoma patient? administrator 0 Views • 2 years ago

In this presentation from Lymphoma & Myeloma 2016, Dr. Lisa Giulino Roth discusses how to best approach the treatment of an adolescent/young adult Hodgkin lymphoma patient.

Earn CME credit for a related activity at the following location:
http://elc.imedex.com/ELC/Spec....ialty-Search.aspx?se

© 2016 Imedex, LLC.

Hodgkin's Lymphoma more prevalent in teens
Hodgkin's Lymphoma more prevalent in teens administrator 0 Views • 2 years ago

2 local teens share their stories with Channel 2's Jackie Roberts.
Epigenetic aging and neurocognitive function in Hodgkin lymphoma survivors
Epigenetic aging and neurocognitive function in Hodgkin lymphoma survivors administrator 2 Views • 2 years ago

Long-term survivors of pediatric Hodgkin lymphoma (HL) are at elevated risk for cardiopulmonary morbidity and cognitive impairment, which can ultimately result in accelerated aging and premature onset of dementia. At ASH, AnnaLynn Williams, PhD, of the Wilmot Cancer Institute, University of Rochester School of Medicine and Dentistry, Rochester, NY, presents results of a study examining the association between biological aging and neurocognitive function in survivors of pediatric cancer. The study included 215 survivors of pediatric HL and 282 community controls from the St. Jude Lifetime Cohort. Participants completed a comprehensive neuropsychological battery and provided a blood sample. Survivors of HL had significantly greater epigenetic age acceleration (EAA) compared to community controls. Among HL, EAA was associated with worse visual-motor processing speed, with those in the second and third tertile performing on average 0.42 and 0.55 standard deviations worse, respectively than HL survivors in the first tertile. Moreover, those in the second and third tertiles performed worse on short-term memory and verbal fluency than those in the first tertile. Overall, results demonstrated that survivors of pediatric HL experience significant EAA associated with several neurocognitive functions. As a result, EAA may be a useful biomarker to identify survivors at risk for accelerated cognitive aging and as a pre-clinical measure for interventions designed to improve cognitive function. This press briefing took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Mr. Arpit Mishra | Hodgkin's Lymphoma Treatment
Mr. Arpit Mishra | Hodgkin's Lymphoma Treatment administrator 1 Views • 2 years ago

Arpit Mishra suffered from a blood disease. In order to treat this disease he underwent a bone marrow transplant surgery under the supervision of Dr. Dr. Vikas Dua Additional Director & Head, Blood Disorders Fortis Memorial Research Institute, Gurugram. Watch this video to know about his experience.
Jason & Heidi, Hodgkin's Lymphoma Survivor and His Wife
Jason & Heidi, Hodgkin's Lymphoma Survivor and His Wife administrator 0 Views • 2 years ago

To get past cancer, you push yourself harder than you ever thought possible. So do we at the UW Cancer Center at ProHealth Care. Relentlessly collaborating to bring you more specialists, personalized treatments and lifesaving alternatives. All so you can put cancer behind you. See the inspiring stories of our patients and our cancer care team at RelentlessTogether.org.
Showing 12 out of 13